Sanbexin

Sanbexin
Product Description

Sanbexin is indicated for the improvement of neurological symptoms, activities of daily living and dysfunction caused by acute cerebral infarction. Category 1 innovative drug with solid medical evidence support. It takes only 5 months from launch to NRDL list. It can improve the neurological function of stroke patients by inhibiting oxidative stress damage and inflammatory damage.

Read more Show less

Jiangsu Simcere Pharmaceutical Co., Ltd.

  • Country/Region:
    China
  • On CPHI since:
    2019
  • Employees:
    5000+
Company types
Pharmaceutical company
View company profile
Categories
more categories Show less

Jiangsu Simcere Pharmaceutical Co., Ltd.

  • Country/Region:
    China
  • On CPHI since:
    2019
  • Employees:
    5000+
Company types
Pharmaceutical company
View company profile

More Products from Jiangsu Simcere Pharmaceutical Co., Ltd. (2)

  • Enlength

    Product Enlength

    As a cornerstone drug for the treatment of multiple myeloma, Bortezomib is used throughout the induction, consolidation and maintenance therapies for myeloma. In 2020, Bortezomib was recommended as a first-line drug for the full management of multiple myeloma in the Guidelines for Diagnosis and Treatm...
  • Lenvatinib Mesilate Capsules

    Product Lenvatinib Mesilate Capsules

    This product is suitable for patients with unresectable hepatocellular carcinoma who have not previously received systemic therapy.The pivotal study of lenvatinib mesylate excluded patients with HCC amenable to local therapy, for whom no study data are available.